• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Cost Per Patient And Budget Impact Prediction Of Denosumab Versus Zoledronic Acid In Prevention Of Skeletal-Related Events (SREs) In Patients With Bone Metastases From Solid Tumours In Portugal And Sweden
 

Cost Per Patient And Budget Impact Prediction Of Denosumab Versus Zoledronic Acid In Prevention Of Skeletal-Related Events (SREs) In Patients With Bone Metastases From Solid Tumours In Portugal And Sweden

on

  • 417 views

Lothgren Mickael, Cristino Joaquim, Lundkvist Jonas, Vrouchou Polina, Bracco Andrea, Pereira João Cost Per Patient And Budget Impact Prediction Of Denosumab Versus Zoledronic Acid In Prevention Of ...

Lothgren Mickael, Cristino Joaquim, Lundkvist Jonas, Vrouchou Polina, Bracco Andrea, Pereira João Cost Per Patient And Budget Impact Prediction Of Denosumab Versus Zoledronic Acid In Prevention Of Skeletal-Related Events (SREs) In Patients With Bone Metastases From Solid Tumours In Portugal And Sweden

Statistics

Views

Total Views
417
Views on SlideShare
417
Embed Views
0

Actions

Likes
0
Downloads
6
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Cost Per Patient And Budget Impact Prediction Of Denosumab Versus Zoledronic Acid In Prevention Of Skeletal-Related Events (SREs) In Patients With Bone Metastases From Solid Tumours In Portugal And Sweden Cost Per Patient And Budget Impact Prediction Of Denosumab Versus Zoledronic Acid In Prevention Of Skeletal-Related Events (SREs) In Patients With Bone Metastases From Solid Tumours In Portugal And Sweden Document Transcript